Skip to content

iRadimed IRMD Free cash flow

Free cash flow at other companies

GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$112M+14.3%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
ICU Medical logo
ICU MedicalICUI
$27.61M-24.8%
ITG
Integer HoldingsITGR
$737K-87.8%
Lumexa Imaging Holdings, Inc.
 logo
Lumexa Imaging Holdings, Inc. LMRI
-$2.38M+84.1%
RadNet logo
RadNetRDNT
$9.04M+223%

Other financials

Income statement

See full
Revenue$22.0M+12.6%
Gross profit$16.8M+13.3%
Operating income$7.2M+33.2%
Net income$5.8M+24.1%
EPS (diluted)$0.45+21.6%

Balance sheet

See full
Cash & equivalents$56.4M+12.0%
Total debt$59.2K-96.9%
Total equity$98.5M+9.4%
Total assets$114.4M+12.4%

Cash flow

See full
Operating cash flow$8.3M+93.2%
CapEx$403.0K-89.1%

Valuation

See full
Market cap$1.21B+84.4%
P/E51.3×+18.1×
P/S14×+5.3×

Profitability

See full
Gross margin76.8%-0.1pp
Operating margin32.4%+2.3pp
Net margin27.4%+1.0pp
FCF margin28.4%+8.9pp

Returns & leverage

See full
Return on equity25%+1.2pp
Debt / equity0.0×
Current ratio7.1×-1.7×

Where this comes from

Calculated from iRadimed’s reported figures.

The official record: iRadimed’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRadimed's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRadimed's free cash flow?
iRadimed (IRMD) reported free cash flow of $7.89M in Q1 2026.
How has iRadimed's free cash flow changed year-over-year?
iRadimed's free cash flow increased by 1225.5% year-over-year, from $595K to $7.89M.
What is the long-term trend for iRadimed's free cash flow?
Over 4 years (2021 to 2025), iRadimed's free cash flow has grown at a 12.4% compound annual growth rate (CAGR), from $10.78M to $17.18M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.